Can Aarti sustain momentum as capacity ramps and stamp duty clouds clarity?
Q1's 38% revenue growth and 65% PAT surge set a high bar. On-plan Q2 would mean continued API strength and early traction from the Tarapur Unit 5 expansion—offset by a ₹59.5 Cr stamp duty order that management is contesting.
The Setup
Aarti Pharmalabs reported a blowout Q1 FY27 on August 7: consolidated revenue jumped 38.7% YoY to ₹535.80 Cr (against a restated FY26 Q1 base of ₹386.19 Cr), while PAT surged 65.4% YoY to ₹76.14 Cr, expanding margins to 25.4% OPM. The company attributed growth to strong API demand and improved capacity utilization from its CDMO (contract manufacturing) business. Management expects this trajectory to continue through H2 FY27 if the API upcycle and CDMO orders sustain—and the newly commissioned Tarapur Unit 5 manufacturing block (3600 TPA for Xanthine derivatives, announced June 30) reaches commercial run rate by Q3 or Q4.
Q2 will test whether that momentum holds. The Street consensus is more measured: analysts project 15–20% FY27 PAT growth (full-year), implying Q2 expectations closer to 20–30% rather than Q1's exceptional 65%. A strong quarter would mean revenue in the ₹500–540 Cr range with OPM sustained near 25%, signaling API demand remains resilient and CDMO margins are sticky. A weak quarter would be revenue below ₹480 Cr or OPM compression below 23%, suggesting demand moderation or CDMO pricing pressure.
~₹500–540 Cr
On-plan would track Q1's 38%+ YoY growth trajectory if API/CDMO momentum persists
~23–25.5%
Sustained if product mix stays favorable and capacity leverage continues from Tarapur ramp
~₹55–70 Cr (est.)
FY27 full-year consensus targets 15–20% growth; Q2 would need ~25%+ YoY to hit that
Monitor
Q2 FY26 saw ₹7.4 Cr forex loss; watch if INR volatility recurs
On Track for FY27?
Aarti Pharmalabs is on the growth vector for FY27. Q1's 38.7% revenue growth and 25.4% OPM far exceed the Street's base case of 15–20% PAT growth, suggesting upside if momentum continues. However, the stamp duty order (₹59.5 Cr levied September 2, contested) creates uncertainty: if the writ petition at Gujarat High Court fails, the charge would materially dent FY27 earnings. Management has flagged the challenge, but a loss on the order could pull FY27 PAT growth back to low-single digits, breaking the consensus view. The new Tarapur capacity adds optionality: if CDMO demand sustains and utilization climbs in H2, it could offset any margin normalization from API price moderation.
What the Street Says
Since Last Quarter
Operational: Tarapur Unit 5 manufacturing block inaugurated (June 30) with 3600 TPA Xanthine capacity, part of broader capex to unlock API/CDMO scaling. This is positive for H2 utilization and medium-term growth, but ramp risk exists.
Regulatory & Legal: Stamp duty order for ₹59.5 Cr issued by the Office of Superintendent of Stamps, Gandhinagar (Aug 29, notified Sep 2). Aarti filed a Writ Petition at Gujarat High Court (Sep 30) challenging the order. No ruling yet; watch Q2 commentary for management's confidence in the outcome. This is the single largest tail risk to FY27 earnings.
Corporate Governance: 7th AGM held Sep 22. Director Rajendra Gogri (Non-Executive, Non-Independent) stepped down. Nomination & Remuneration Committee reconstituted effective Oct 1. Board-level changes are routine, but flag any management commentary on strategy or capex.
Capital Actions: Final dividend of 40% (₹2.00 per share) for FY26 approved; record date Sep 15. Trading window for Q2 results closed Sep 28 (routine for insider trading compliance).
Ownership: Promoter shareholding stable near 42.9%; FII 8.17% in Q1 (slight dip from Q4's 8.39%); DII 7.22% (slight dip from Q4's 7.41%). No material pledging or insider buying/selling noted in recent bulk/block deals. Bulk activity in mid-Sep around ₹820–904, largely two-way flow (buying by UNIFI CAPITAL, QE SECURITIES, MICROCURVES; selling by JASMINE FAMILY TRUST, QE in Sep 18 cross).
What to Watch on Result Day (Oct 28)
1 · Revenue & margin beat?
Does Q2 deliver ₹500+ Cr revenue and sustain 24%+ OPM, or is there moderation? Watch management's tone on API pricing and CDMO pipeline for H2.
2 · Tarapur Unit 5 ramp trajectory
Any update on capacity utilization, customer pull, or expected contribution timing? Early signs of traction vs delays would set tone for FY27 guidance.
3 · Stamp duty order update
Has the Gujarat High Court writ petition progressed? Management confidence in overturning the ₹59.5 Cr order, or should investors model a potential loss? This alone could swing FY27 guidance.
4 · FY27 guidance / management commentary
Do they reaffirm the 15–20% FY27 PAT growth consensus, or revise higher (Q1 trajectory) or lower (stamp duty risk)? Watch for capex updates and any commentary on API/CDMO market conditions.
5 · Forex & other P&L items
Q2 FY26 saw a ₹7.4 Cr forex loss; is that a one-off or a structural headwind? Look for hedging disclosure or currency sensitivity notes.
Aarti Pharmalabs enters Q2 results on a strong growth footing—Q1's 38% revenue and 65% profit surge positioned the stock as a post-covid recovery play with operating leverage. But clarity is clouded by the contested ₹59.5 Cr stamp duty order and the execution risk on the new Tarapur capacity. Q2 will test whether management can hold margins and API momentum, or whether the easy comps and CDMO demand are normalizing. A beat (₹510+ Cr revenue, 25%+ OPM, PAT beat consensus by 10%+) would justify the 12-month ₹920–970 target and refresh the bulls. A miss—especially on margins or if the stamp duty ruling goes against Aarti—risks a sharp re-rate toward the low ₹750s.
Informational and educational content only. Not investment advice.